PROVECTUS BIOPHARMACEUTICALS, INC.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

PVCT$0.04-17.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

For the Three Months Ended · For the Nine Months Ended
September 30, · September 30,
2026 · 2025 · 2026 · 2025
Grant Revenue	$	-	$	-	$	-	$336,108
Operating Expenses:
Research and development		240,320		345,861		704,784	1,628,848
General and administrative		971,045		929,746		2,693,162	2,881,536
Total Operating Expenses		1,211,365		1,275,607		3,397,946	4,510,384
Total Operating Loss		(1,211,365)		(1,275,607)		(3,397,946)	(4,174,276)
Other Income (Expense):
Research and development credit		-		-		281	-
Interest expense		(62,345)		(48,022)		(165,710)	(163,036)
Total Other Expense, Net		(62,345)		(48,022)		(165,429)	(163,036)
Net Loss		(1,273,710)		(1,323,629)		(3,563,375)	(4,337,312)
Net Loss attributable to noncontrolling interest		(7,434)		(12,348)		(24,079)	(71,503)
Net Loss attributable to common stockholders		$(1,266,276)		$(1,311,281)		$(3,539,296)	$(4,265,809)
Basic and Diluted Loss Per Common Share		$(0.00)		$(0.00)		$(0.01)	$(0.01)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted		420,279,879		420,279,879		420,279,879	420,279,879

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.